A midsize acquisition seems imminent, and these two would fit like a glove.
News & Analysis: Sage Therapeutics
Earning the first FDA approval for treating postpartum depression is a big step, but it's hardly an express ticket to profit town.
SAGE earnings call for the period ending December 31, 2018.
The pharma company reported positive results from an important phase 3 trial.
These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.
These stocks skyrocketed following exciting announcements.
The tiny pharma company reported promising results in a study for its lead drug candidate, eliciting comparisons to a reputable high-flying peer.
Stocks advanced, with Eil Lilly buying Loxo Oncology and Sage Therapeutics reporting a clinical trial success.
The biotech reported great clinical results for a late-stage drug.
Consider putting these large-cap, mid-cap, and small-cap biotech stocks on your buy list.